Abstract:Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice's survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine's protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.

Effective Production and Purification of the Glycosylated TSOL18 Antigen, Which is Protective Against Pig Cysticercosis

Research Article an Improved Bac-to-Bac/BmNPV Technology Expressing Envelope E2 Glycoprotein of Classical Swine Fever Virus (CSFV) in the Silkworm, Bombyx Mori

Immunization with Excreted–secreted Antigens Reduces Tissue Cyst Formation in Pigs

A Long-Lasting Protective Immunity Against Chronic Toxoplasmosis in Mice Induced by Recombinant Rhoptry Proteins Encapsulated in Poly (Lactide-Co-glycolide) Microparticles.

Analysis of immune response in BALB/c mice immunized with recombinant plasmids pMZ-X3-Ts14–3–3.3 and pMZ-X3-sp-Ts14–3–3.3 of Taenia solium

Molecular expression and characterization of Taenia solium TS14 gene for sensitive detection of porcine cysticercosis

Development of a Point-of-Care Immunochromatographic Test Based on Rhoptry Protein 14 for Serological Detection of Toxoplasma Gondii Infection in Swine

ELISA and immunoblot using purified glycoproteins for serodiagnosis of cysticercosisin pigs naturally infected with Taenia solium

Development of a Dot Immunogold Filtration Assay for Cysticercosis

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Optimization of In-House Indirect-ELISA & EITB Assays Employing Cysticercus cellulosae Antigens for Serological Detection and PCR Assays for Molecular Detection of Porcine Cysticercosis

Ginseng Stem-and-Leaf Saponin (GSLS)-Enhanced Protective Immune Responses Induced by Toxoplasma gondii Heat Shocked Protein 70 (HSP70) Against Toxoplasmosis in Mice

Proteomic analysis of Taenia solium cysticercus and adult stages

[Cloning, Expression and Prediction of Protein Structure of Ts3 Gene of Cysticercus Cellulosae].

Development of an Immunochromatographic Test Based on Monoclonal Antibodies Against Surface Antigen 3 (tgsag3) for Rapid Detection of Toxoplasma Gondii

Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination

Immunogenicity of recombinant Bacillus subtilis spores expressing Clonorchis sinensis tegumental protein

Optimization of Prokaryotic Expression of Excretory-secretory Antigen Ts8B1 Protein Gene in Cysticercus Cellulosae

Control of the taeniosis/cysticercosis complex: future developments

Characterization of antigenic proteins of the Taenia solium postoncospheral form

Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis